Iressa. Game over. Targeted failure of AstraZeneca

MADRID, Sept 28 (Reuters) - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit.

Some doctors had hoped that extending the use of Iressa in combination with chemotherapy would help to keep cancers at bay, even when tumour cells had started to develop resistance to the drug.

But a clinical study presented at the European Society for Medical Oncology annual congress on Sunday found no statistically significant improvement in the length of time patients lived without their disease getting worse.

The Phase III study, involving 265 patients, tested Iressa plus chemotherapy to chemotherapy alone. It was sponsored by AstraZeneca.

http://news.yahoo.com/no-benefit-continued-astrazenecas-iressa-065959911.html

Sweet dream of a macho...

Fake?

Quote of the day. Drug development in post-modern

The R&D infrastructure for drug development is shrinking, perhaps irreversibly, and our ability to discover and develop new medicines is being progressively dismantled.

http://medicalxpress.com/news/2014-09-drugs-fundamentally-future.html

Is Peter Thiel a communist? Quote of the day.

You have to think of companies like Microsoft or Oracle or Hewlett-Packard as fundamentally bets against technology. They keep throwing off profits as long as nothing changes. Microsoft was a technology company in the ’80s and ’90s; in this decade you invest because you’re betting on the world not changing. Pharma companies are bets against innovation because they’re mostly just figuring out ways to extend the lifetime of patents and block small companies.

http://pipeline.corante.com/archives/2014/09/19/peter_thiels_uncomplimentary_views_of_big_pharma.php

More money to rhe masses!

What plan? Fake?

Fake?

Fake and propaganda!

Another propaganda story...

Clinical trial data fraud... Surprised?

The company has uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result. Additional evidence indicates that the biostatistics firm and certain Andromeda employees continued the improper practice of sharing and examining un-blinded data from the ongoing DIA-AID 2 trial. All of these acts were concealed from Hyperion and others.

The Company has suspended the Andromeda employees known to be involved, is notifying relevant regulatory authorities, and continues to investigate in order to explore its legal options. Hyperion employees were not involved in any of the improper conduct.

 

http://pipeline.corante.com/archives/2014/09/10/clinical_trial_fraud.php

 

Quote of the day

Cooking with... Fake?

We lose - you win. Sign here...

Propaganda!

AZ are communists? No way!

If you were wondering why the White House suddenly took an interest in the consequences of tax inversion deals last spring, here is the reason – a pair of Wall Streeters with ties to the Obama administration made some calls on behalf of AstraZeneca which, you may recall, was trying to fend off an unwanted bid from Pfizer. Pfizer cited a tax inversion as one reason for its offer.

http://blogs.wsj.com/pharmalot/2014/09/04/astrazeneca-called-the-white-house-to-say-stop-those-tax-inversions/